BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board

Rhea-AI Summary

PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board effective December 1, 2024. Dr. Gallagher brings over 25 years of experience in biotech and pharmaceutical investments, having served as Managing Partner at Trekk Venture Partners and Partner at Abingworth. His notable achievements include overseeing Sirtris Pharmaceuticals' $720 million acquisition by GlaxoSmithKline and contributing to Translate Bio's $3.2 billion acquisition by Sanofi.

Dr. Gallagher holds a Ph.D. in Organic Chemistry from the University of Michigan and has served as Chairman of eFFECTOR Therapeutics. His expertise spans venture capital, strategic investments, and corporate development within the biotech sector.

Positive

• Addition of experienced biotech investor with 25+ years of industry expertise
• Track record of successful exits including $720M and $3.2B acquisitions
• Brings valuable venture capital and corporate development experience

Negative

• None.

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed as an independent director effective on 1 December, 2024.

Stephen Van Deventer, CEO of BioGene, commented:

"We are excited to welcome Dr. Brian Gallagher, Jr. to our Corporate Advisory Board. Brian's extensive leadership in venture capital, strategic investments, and corporate development within the biotech and pharmaceutical sectors brings a wealth of expertise to BioGene. His proven track record in supporting innovative companies and driving them toward transformative success aligns perfectly with our vision of delivering groundbreaking therapies."

Dr. Brian Gallagher, Jr.'s Career Highlights:

Dr. Gallagher is a seasoned investor and entrepreneur with over 25 years of experience in biotech and pharmaceutical investments. He has held key leadership roles, including Managing Partner and Co-Founder of Trekk Venture Partners and Partner at Abingworth, a trans-Atlantic venture capital firm. Dr. Gallagher's expertise spans from overseeing investments in early-stage biotech companies to leading corporate development initiatives at Sirtris Pharmaceuticals, where he played a pivotal role in its $720 million acquisition by GlaxoSmithKline.

As a recognized leader in venture capital, Dr. Gallagher has successfully guided companies from seed investment to public offerings, including serving as Chairman of the Board at eFFECTOR Therapeutics (NASDAQ: EFTR). His strategic insights have contributed to numerous high-profile exits, including Translate Bio's acquisition by Sanofi for $3.2 billion. Dr. Gallagher has also served on advisory boards at leading institutions, including the University of Michigan Biomedical Venture Fund and the National Brain Tumor Society.

Dr. Gallagher earned his Ph.D. in Organic Chemistry from the University of Michigan and a B.S. in Chemistry from the University of Massachusetts, Amherst. He is widely published in peer-reviewed journals and holds multiple patents related to drug development.

Dr. Gallagher remarked on his appointment:

"I am honored to join BioGene's Corporate Advisory Board and contribute to the Company's mission of advancing innovative therapies. BioGene's commitment to addressing critical unmet medical needs through cutting-edge science is truly inspiring. I look forward to supporting their strategic initiatives and growth trajectory."

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.

About BioGene Therapeutics Inc.

BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5% R&D tax cashback incentive. This subsidiary supports ongoing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.

On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer

For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com

Forward-Looking Statements:

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232408

FAQ

When did Dr. Brian Gallagher join PreveCeutical Medical (PRVCF) as advisor?

Dr. Brian Gallagher joined PreveCeutical Medical's subsidiary BioGene Therapeutics as a Corporate Advisory Board member effective December 1, 2024.

What is Dr. Gallagher's experience in the biotech industry before joining PRVCF?

Dr. Gallagher has over 25 years of experience in biotech and pharmaceutical investments, serving as Managing Partner at Trekk Venture Partners and Partner at Abingworth, and was involved in major acquisitions including Sirtris Pharmaceuticals ($720M) and Translate Bio ($3.2B).

What are Dr. Gallagher's educational qualifications for his role at PRVCF?

Dr. Gallagher holds a Ph.D. in Organic Chemistry from the University of Michigan and a B.S. in Chemistry from the University of Massachusetts, Amherst.